ClinicalTrials.gg
RecruitingNCT06268132Updated Feb 22, 2024

Longevity in Russia

An observational study in LONGEVITY 1, Frailty and Aging, sponsored by Center for Strategic Planning, of the Federal Medical and Biological Agency. Recruiting at 1 site in Russian Federation. Open to participants aged 90 Years and older. Per ClinicalTrials.gov, last updated 2024-02-22.

Sponsored by Center for Strategic Planning, of the Federal Medical and Biological Agency · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 10 months ago, but the record still lists the study as recruiting.
  • Started Dec 2019; still recruiting 6 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
4,000
Ages
90 Years and older
Sex
All
01

Study summary

This is an observational cohort study of long-living adults (participants aged 90 and above) from the Central Federal District of Russia.

The study seeks to determine the genetic and cellular and molecular determinants of healthy longevity and to assess the impact of lifestyle and socioeconomic and environmental factors on healthy longevity.

The study is expected to result in the development of a panel of markers of healthy longevity and/or a model of healthy aging based on the analysis of all factors under consideration.

Read the detailed description

The study involves a long-term observation of a cohort of long-living adults. During the first visit, a medical professional will take a detailed medical history and perform a comprehensive geriatric assessment (for 15 geriatric syndromes), and physical examination. The participants will have their biomaterials sampled for basic and extended blood biochemistry testing, telomere length measurement, common urine tests and subsequent biobanking and additional studies: whole genome sequencing, DNA methylation analysis, transcriptome analysis, and 16S RNA sequencing of stool and saliva.

Follow-up checks will be carried out once a year by phone or during additional visits.

The study seeks to identify the genetic, epigenetic, and metagenomic determinants associated with the successful and unsuccessful aging phenotypes, mortality, and survival in long-living individuals.

02

Conditions studied

  • LONGEVITY 1
  • Frailty
  • Aging
  • Age-related Cognitive Decline
  • Aging Disorder

Browse trials for

03

In context

Frailty

1,291 studies on the registry are indexed under Frailty; 454 are open to participants now.

This study's planned enrollment of 4,000 is above the median of 225 across 495 observational studies indexed under Frailty.

Browse Frailty studies →

Lead sponsor

Center for Strategic Planning, of the Federal Medical and Biological Agency is the lead sponsor of 2 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
90 Years and older
Sexes eligible
All
Sampling method
Non-probability sample

Study population

The inclusion of participants will be carried out with the involvement of social services, boarding houses for labor veterans, geriatric centers and other geriatric services in the central region of Russia

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 90 years of age or above

Exclusion criteria

Exclusion Criteria:

  • Refusal to participate or to provide ;
  • Any other criteria deemed reasons for exclusion by the Principal Investigator.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
4,000 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Long-living individuals

    Long-living individuals at least 90 years of age from the Central Federal District of Russia

06

What researchers measure

Primary outcomes

  1. Mortality among long-living adults

    Mortality among long-living adults within at least 1 year after inclusion in the study and factors associated with mortality will be assessed.

    Time frame: at least 1 year after inclusion in the study

  2. Morbidity among long-living adults

    Morbidity among long-living adults within at least 1 year after inclusion in the study and factors associated with morbidity will be assessed.

    Time frame: at least 1 year after inclusion in the study

Secondary outcomes

  1. Aging phenotypes

    Identification of successful and unsuccessful aging phenotypes

    Time frame: at least 2 years after inclusion in the study

  2. Social, economic, and medical- history-related determinants

    Identification of social, economic, and medical- history-related determinants of successful and unsuccessful aging, geriatric syndromes

    Time frame: at least 2 years after inclusion in the study

  3. Genetic determinants

    Identification of the genetic determinants of successful and unsuccessful aging, geriatric syndromes

    Time frame: at least 2 years after inclusion in the study

  4. Epigenetic determinants

    Identification of the epigenetic determinants (methylation sites) of successful and unsuccessful aging, geriatric syndromes

    Time frame: at least 2 years after inclusion in the study

  5. Metagenomic determinants

    Identification of the metagenomic determinants (16S-rSeq) of successful and unsuccessful aging, geriatric syndromes

    Time frame: at least 2 years after inclusion in the study

07

Study locations

1 of 1 sites recruiting
  • RUSSIAN CLINICAL AND RESEARCH CENTER OF GERONTOLOGY, Pirogov Russian National Research Medical University of the Ministry of Healthcare of the Russian Federation
    Moscow, 129226, Russian Federation
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2019 (actual). Primary completion is estimated for Dec 2024, 60 months after the start.

Of 291 non-industry observational studies under Frailty, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 55. This study's planned 60 months is above that.

Counting every sponsor, half of 294 studies reached it within 29 months; a quarter within 12 and three quarters within 55.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 13, 2024
First posted
Feb 20, 2024
StartActual
Dec 25, 2019
Primary completionEst.
Dec 31, 2024
CompletionEst.
Dec 31, 2025
Last update
Feb 22, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 22, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06268132
Lead sponsor
Center for Strategic Planning, of the Federal Medical and Biological Agency
Collaborators
Pirogov Russian National Research Medical University
Responsible party
Sponsor
First posted
Feb 20, 2024
Start date
Dec 25, 2019
Primary completion
Dec 31, 2024 (estimated)
Completion
Dec 31, 2025 (estimated)
Last update
Feb 22, 2024

Study contacts

Daria A. Kashtanova, M.D., Ph.D
Contact
DKashtanova@cspfmba.ru
+74955406171 ext. 4120
Veronika V. Erema, M.D., Ph.D
Contact
VErema@cspfmba.ru
+7 (495) 540-61-71 ext. 4136
Irina D. Strazhesko, M.D., Ph.D
principal investigator · Pirogov Russian National Research Medical University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion